EFFECTS OF DIFFERENT DOSES OF ATORVASTATIN ON BLOOD LIPIDS, CARDIAC FUNCTION AND PROGNOSIS IN ELDERLY PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

Jie Fu^*, Li-zhi Liu, Cao-jie Lu, Dan Zhang

Department of Vasculocardiology, Fenghua People's Hospital of Ningbo City, Zhejiang Province, Ningbo 315500, China

Objective: To observe the effects of different doses of atorvastatin on blood lipids, the recovery of cardiac function and disease prognosis in elderly patients with acute myocardial infarction (AMI).

Methods: A total of 188 elderly patients with AMI admitted to our hospital from June 2017 to December 2018 were divided into an observation and control group according to different doses of atorvastatin, with each group including 94 cases. The control group was treated with a conventional dose of atorvastatin (20mg/d), while the observation group was treated with a double dose of atorvastatin (40mg/d). The blood lipids, peripheral hypersensitive C-reactive protein (hs-CRP), alanine aminotransferase (ALT), 24h urinary microalbumin (UMA) and related cardiac function indexes were measured before treatment, 1 month and 6 months after treatment. The major adverse cardiovascular events (MACEs) and adverse reactions were analysed and compared between the two groups at a 12-month follow-up.

Results: Before treatment, there were no significant differences in peripheral blood total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), ALT, hs-CRP, 24h UMA, cardiac troponin I (cTnI), creatine kinase isoenzyme (CK-MB), left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) between the two groups (P>0.05). After 1 month and 6 months of treatment, the levels of TC, LDL-C, hs-CRP, 24 UMA, I (cTnI) and LVEF in the observation group were significantly lower than those of the control group, while ALT level in the observation group was significantly higher than that of the control group (P<0.05). However, no significant differences in the incidence of MACEs and adverse reactions were observed between the two groups (P>0.05).

Conclusion: Both the conventional dose and double dose of atorvastatin can be used for elderly AMI patients to effectively improve cardiac function, though the latter has a more obvious lipid-lowering effect.